Conference Call and Webcast Scheduled for 8:30 AM ET
NEW YORK--(BUSINESS WIRE)--Feb. 21, 2019--
UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report
fourth quarter and full year 2018 financial results on Thursday,
February 28, 2019, prior to the open of the market. The announcement
will be followed by a live audio webcast and conference call at 8:30AM
Eastern Time.
Audio Webcast
The webcast will be made available on the Investors section of the
Company’s website at http://investors.urogen.com.
Following the live audio webcast, a replay will be available on the
Company's website for approximately two weeks.
Dial-In Information
Live (U.S. / Canada): 1 (888) 771-4371
Live (International): 1
(847) 585-4405
Confirmation number: 48205742
About UroGen Pharma Ltd.
UroGen Pharma Ltd. (Nasdaq:URGN) is a clinical-stage biopharmaceutical
company developing advanced non-surgical treatments to address unmet
needs in the field of urology, with a focus on uro-oncology. UroGen has
developed RTGel™, a proprietary sustained release, hydrogel-based
platform technology that has the potential to improve therapeutic
profiles of existing drugs. UroGen’s sustained release technology is
designed to enable longer exposure of the urinary tract tissue to
medications, making local therapy a potentially more effective treatment
option. UroGen’s lead investigational candidates, UGN-101 (mitomycin
gel) for instillation, and UGN-102 (mitomycin gel) for intravesical
instillation, are designed to potentially ablate tumors by non-surgical
means and to treat several forms of non-muscle invasive urothelial
cancer, including low-grade upper tract urothelial cancer and bladder
cancer, respectively. UroGen is headquartered in New York, NY with
operations in Los Angeles, CA and Israel.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190221005281/en/
Source: UroGen Pharma Ltd.
UROGEN CONTACT:
Kate Bechtold
Director, Corporate
Communications & Investor Relations
Kate.Bechtold@urogen.com
914-552-0456
